Literature DB >> 21762125

Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome.

R Bertelli1, M Bodria, M Nobile, S Alloisio, R Barbieri, G Montobbio, P Patrone, G M Ghiggeri.   

Abstract

Activation of the oxidative burst and failure of CD4(+) CD25(+) cell regulation have been implicated in idiopathic nephrotic syndrome (iNS). The intimate mechanism is, however, unknown and requires specifically focused studies. We investigated reactive oxygen species (ROS) generation [di-chlorofluorescein-diacetate (DCFDA)] fluorescence assay and the regulatory adenosine 5'-triphosphate (ATP) pathways in the blood of 41 children with iNS, utilizing several agonists and antagonists of nucleotide/nucleoside receptors, including the addition of soluble apyrase. The CD4(+) CD25(+) CD39(+) /CD73(+) expression was determined in vivo in parallel during disease activity. Overall, we found that the percentage of CD39(+) CD4(+) CD25(+) was reduced markedly in iNS by 80% (3·43±0·04% versus 13·14±0·07% of total lymphocytes, P<0·001). In these patients, reactive oxygen species (ROS) generation by polymorphonuclear neutrophils (PMN) at rest was a function of apyrase (CD39) expressed by CD4(+) CD25(+) , with higher rates in patients with very low CD39(+) CD4(+) CD25(+) levels (<7·5%). Addition of apyrase reduced ROS generation by 40% in both iNS and controls and was mainly effective in patients. The quota of ROS surviving ATP elimination was higher still in iNS. In vitro studies to limit ROS generation with adenosine analogues (2'-chloroadenosine and 5'-N-ethylcarboxamidoadenosine) produced minor effects. At variance, antagonizing ATP efflux with carbenoxolone or by antagonizing ATP effects (Brilliant Blue G, KN62 and A437089) reduced ROS generation comparable to apyrase. These results confirm a key role of ATP in the regulation of innate immunity and minimize the effect of adenosine. Decreased CD39(+) CD4(+) CD25(+) expression in iNS highlights an impairment of ATP degradation in this pathology. However, high ROS surviving ATP consumption implies a major role of other regulatory pathways.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762125      PMCID: PMC3193919          DOI: 10.1111/j.1365-2249.2011.04441.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  52 in total

1.  P2X7 nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils.

Authors:  B C Suh; J S Kim; U Namgung; H Ha; K T Kim
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  Commercially available firefly luciferase reagents.

Authors:  F R Leach; J J Webster
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Letter: Lymphokines and nephrotic syndrome.

Authors:  G Lagrue; S Xheneumont; A Branellec; B Weil
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

4.  Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome.

Authors:  R Bertelli; A Trivelli; A Magnasco; M Cioni; M Bodria; A Carrea; G Montobbio; G Barbano; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2010-05-19       Impact factor: 4.330

Review 5.  Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics.

Authors:  Isabella Dalle-Donne; Andrea Scaloni; Daniela Giustarini; Eleonora Cavarra; Gianluca Tell; Giuseppe Lungarella; Roberto Colombo; Ranieri Rossi; Aldo Milzani
Journal:  Mass Spectrom Rev       Date:  2005 Jan-Feb       Impact factor: 10.946

6.  COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.

Authors:  Francesca Diomedi-Camassei; Silvia Di Giandomenico; Filippo M Santorelli; Gianluca Caridi; Fiorella Piemonte; Giovanni Montini; Gian Marco Ghiggeri; Luisa Murer; Laura Barisoni; Anna Pastore; Andrea Onetti Muda; Maria Luisa Valente; Enrico Bertini; Francesco Emma
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

7.  Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events.

Authors:  T Bertani; A Poggi; R Pozzoni; F Delaini; G Sacchi; Y Thoua; G Mecca; G Remuzzi; M B Donati
Journal:  Lab Invest       Date:  1982-01       Impact factor: 5.662

Review 8.  Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.

Authors:  M Sitkovsky; D Lukashev; S Deaglio; K Dwyer; S C Robson; A Ohta
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

9.  Nucleotide receptor signalling and the generation of reactive oxygen species.

Authors:  Alma N Guerra; Monica L Gavala; Hun Sun Chung; Paul J Bertics
Journal:  Purinergic Signal       Date:  2007-01-06       Impact factor: 3.765

10.  CD39 and control of cellular immune responses.

Authors:  Karen M Dwyer; Silvia Deaglio; Wenda Gao; David Friedman; Terry B Strom; Simon C Robson
Journal:  Purinergic Signal       Date:  2007-02-06       Impact factor: 3.765

View more
  8 in total

Review 1.  Purinergic signalling in the kidney in health and disease.

Authors:  Geoffrey Burnstock; Louise C Evans; Matthew A Bailey
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 2.  [Minimal change disease and focal segmental glomerulosclerosis].

Authors:  J Müller-Deile; H Schenk; M Schiffer
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

Review 3.  Regulatory T cells and minimal change nephropathy: in the midst of a complex network.

Authors:  R Bertelli; A Bonanni; A Di Donato; M Cioni; P Ravani; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2015-10-12       Impact factor: 4.330

4.  Rituximab in children with resistant idiopathic nephrotic syndrome.

Authors:  Alberto Magnasco; Pietro Ravani; Alberto Edefonti; Luisa Murer; Luciana Ghio; Mirco Belingheri; Elisa Benetti; Corrado Murtas; Giovanni Messina; Laura Massella; Maria Gabriella Porcellini; Michela Montagna; Mario Regazzi; Francesco Scolari; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

5.  LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity.

Authors:  Roberta Bertelli; Armando Di Donato; Michela Cioni; Fabio Grassi; Masami Ikehata; Alice Bonanni; Maria Pia Rastaldi; Gian Marco Ghiggeri
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

Review 6.  Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease.

Authors:  Roberta Bertelli; Alice Bonanni; Gianluca Caridi; Alberto Canepa; G M Ghiggeri
Journal:  Front Med (Lausanne)       Date:  2018-06-11

7.  Premature birth carries a higher risk of nephrotic syndrome: a cohort study.

Authors:  Chih-Chia Chen; Tsung Yu; Hsin-Hsu Chou; Yuan-Yow Chiou; Pao-Lin Kuo
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

Review 8.  Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions.

Authors:  Ashlene M McKay; Rulan S Parekh; Damien Noone
Journal:  Pediatr Nephrol       Date:  2022-04-28       Impact factor: 3.651

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.